Amyloid Blocker

Amyloid plaques characteristic of the Alzheimer brain contain fibrils composed of amyloid β aggregates. Peptides, small organic molecules and nanoparticles can be used to bind or aggregate amyloid β (Aβ). They have been used as a strategy for the development of pharmaceutical approaches or agents to treat Alzheimer′s disease (AD). Short peptides containing the sequence KLVFF have been shown to bind specifically to the homologous region in Aβ and are used to prevent full length amyloid fibril formation.